PCI Pharma Services is pleased to announce a major expansion of capabilities and capacity in aseptic liquid fill-finish and sterile lyophilization technology, an important manufacturing process commonly used with injectable and biologic therapies, with the investment of $100 million into the construction and enhancement of world-class facilities, at our Bedford, New Hampshire campus.
Our corporate score of 54 is a 70% increase from our previous assessment result and effectively puts PCI among the top 32% of all companies assessed by EcoVadis. The improved rating is a result of the collective effort by the Global ESG Work Team as well as the larger PCI employee base who contributed to the process.
We are pleased to announce the addition of three new exceptional automated sterile fill-finish machines in our San Diego and Melbourne facilities. Purchased from Cytiva, this remarkable equipment can pivot between filling different sterile medications into vials and syringes.
PCI Pharma Services is pleased to announce the construction of a new Clinical Center of Excellence in Bridgewater, Massachusetts providing clinical storage, distribution and packaging to meet the growing New England clinical supply market demands. We are the first global CDMO with integrated end-to-end capabilities to build such a center, with a strong focus on […]
PCI Pharma Services (PCI)is pleased to announce we have signed a definitive agreement to acquire Lyophilization Services of New England, Inc. (LSNE), a premier contract development and manufacturing organization (CDMO) headquartered in Bedford, New Hampshire, from global private equity firm Permira
When it comes to pharmaceutical and biopharmaceutical supply chain expertise who do you trust?Start your PCI experience today.
Your bridge between life-changing therapies and patients.